JACY BEZERRA PARMERA
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/45 - Laboratório de Fisiopatologia Neurocirúrgica, Hospital das Clínicas, Faculdade de Medicina
LIM/45 - Laboratório de Fisiopatologia Neurocirúrgica, Hospital das Clínicas, Faculdade de Medicina
38 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 38
bookPart Demência frontotemporal(2021) BAHIA, Valéria Santoro; PARMERA, Jacy Bezerra- Diagnóstico e manejo da demência da doença de Parkinson e demência com corpos de Lewy: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia(2022) PARMERA, Jacy Bezerra; TUMAS, Vitor; FERRAZ, Henrique Ballalai; SPITZ, Mariana; BARBOSA, Maira Tonidandel; SMID, Jerusa; BARBOSA, Breno José Alencar Pires; SCHILLING, Lucas Porcello; BALTHAZAR, Márcio Luiz Figueiredo; SOUZA, Leonardo Cruz de; VALE, Francisco Assis Carvalho; CARAMELLI, Paulo; BERTOLUCCI, Paulo Henrique Ferreira; CHAVES, Márcia Lorena Fagundes; BRUCKI, Sonia Maria Dozzi; NITRINI, Ricardo; CASTILHOS, Raphael Machado; FROTA, Norberto Anízio FerreiraABSTRACT Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) represent the second most common type of degenerative dementia in patients aged 65 years and older, leading to progressive cognitive dysfunction and impaired quality of life. This study aims to provide a consensus based on a systematic Brazilian literature review and a comprehensive international review concerning PDD and DLB. Moreover, we sought to report on and give recommendations about the best diagnostic approaches focusing on primary and secondary care. Based on the available data, we recommend clinicians to apply at least one brief global cognitive instrument to assess PDD, such as the Mini-Mental State Examination and preferably the Montreal Cognitive Assessment and the Addenbrooke’s Cognitive Examination-Revised. Validated instruments to accurately assess functional abilities in Brazilian PD patients are still incipient. Further studies should focus on biomarkers with Brazilian cohorts.
- Tic Status in Tourette Syndrome Due to Depletion of the Deep Brain Stimulation Battery(2023) PARMERA, Jacy Bezerra; YAMAMOTO, Joyce Yuri Silvestre; CURY, Rubens Gisbert
- Magnetic resonance and dopamine transporter imaging for the diagnosis of Parkinson's disease: a narrative review(2022) OTANI, Rafael Tomio Vicentini; YAMAMOTO, Joyce Yuri Silvestre; NUNES, Douglas Mendes; HADDAD, Monica Santoro; PARMERA, Jacy BezerraBackground: the diagnosis of Parkinson's disease (PD) can be challenging, especially in the early stages, albeit its updated and validated clinical criteria. Recent developments on neuroimaging in PD, altogether with its consolidated role of excluding secondary and other neurodegenerative causes of parkinsonism, provide more confidence in the diagnosis across the different stages of the disease. This review highlights current knowledge and major recent advances in magnetic resonance and dopamine transporter imaging in aiding PD diagnosis. Objective: This study aims to review current knowledge about the role of magnetic resonance imaging and neuroimaging of the dopamine transporter in diagnosing Parkinson's disease. Methods: We performed a non-systematic literature review through the PubMed database, using the keywords ""Parkinson"", ""magnetic resonance imaging"", ""diffusion tensor"", ""diffusion-weighted"", ""neuromelanin"", ""nigrosome-1"", ""single-photon emission computed tomography"", ""dopamine transporter imaging"". The search was restricted to articles written in English, published between January 2010 and February 2022. Results: The diagnosis of Parkinson's disease remains a clinical diagnosis. However, new neuroimaging biomarkers hold promise for increased diagnostic accuracy, especially in earlier stages of the disease. Conclusion: Future validation of new imaging biomarkers bring the expectation of an increased neuroimaging role in the diagnosis of PD in the following years.
conferenceObject Deciphering Corticobasal Syndrome: are clinical features and FDG-PET imaging capable of predicting amiloyd status?(2019) PARMERA, J.; COUTINHO, A.; NETO, A.; ARANHA, M.; ONO, C.; BUCHPIGUEL, C.; NITRINI, R.; BARBOSA, E.; BRUCKI, S.- Probable 4-Repeat Tauopathy Criteria Predict Brain Amyloid Negativity, Distinct Clinical Features, and FDG-PET/MRI Neurodegeneneration Patterns in Corticobasal Syndrome(2024) PARMERA, Jacy Bezerra; CARNEIRO, Camila de Godoi; ALMEIDA, Isabel Junqueira de; OLIVEIRA, Marcos Castello Barbosa de; BARBOSA, Pedro Melo; STUDART-NETO, Adalberto; ONO, Carla Rachel; NITRINI, Ricardo; BUCHPIGUEL, Carlos Alberto; BARBOSA, Egberto Reis; BRUCKI, Sonia Maria Dozzi; COUTINHO, Artur MartinsBackgroundCorticobasal syndrome (CBS) is associated with diverse underlying pathologies, including the four-repeat (4R)-tauopathies. The Movement Disorders Society (MDS) criteria for progressive supranuclear palsy (PSP) proposed the novel category ""probable 4R-tauopathy"" to address the phenotypic overlap between PSP and corticobasal degeneration (CBD).ObjectivesTo investigate the clinical ability of the MDS-PSP criteria for probable 4R-tauopathy in predicting a negative amyloid-PET in CBS. Additionally, this study aims to explore CBS patients classified as 4R-tauopathy concerning their clinical features and neuroimaging degeneration patterns.MethodsThirty-two patients with probable CBS were prospectively evaluated and split into those who fulfilled or did not fulfill the 4R-tauopathy criteria (CBS-4RT+ vs. CBS-4RT-). All patients underwent positron emission tomographies (PET) with [18F]fluorodeoxyglucose and [11C]Pittsburgh Compound-B (PIB) on a hybrid PET-MRI scanner to perform multimodal quantitative comparisons with a control group.ResultsEleven patients were clinically classified as CBS-4RT+, and only one had a positive PIB-PET. The CBS-4RT+ classification had 92% specificity, 52% sensitivity, and 69% accuracy in predicting a negative PIB-PET. The CBS-4RT+ group presented with dysarthria and perseveration more often than the CBS-4RT- group. Moreover, the CBS-4RT+ group showed a prominent frontal hypometabolism extending to the supplementary motor area and striatum, and brain atrophy at the anterior cingulate and bilateral striata.ConclusionsThe 4R-tauopathy criteria were highly specific in predicting a negative amyloid-PET in CBS. Patients classified as 4R-tauopathy presented distinct clinical aspects, as well as brain metabolism and atrophy patterns previously associated with tauopathies.
bookPart Fenomenologia dos movimentos anormais(2021) PARMERA, Jacy Bezerra; HADDAD, Mônica Santoro- Foot-Hand Synkinesis in Corticobasal Syndrome: Single Clinical Feature with Distinct Molecular Imaging Biomarkers(2021) PARMERA, Jacy Bezerra; BRUCKI, Sonia Maria Dozzi; COUTINHO, Artur Martins; NITRINI, Ricardo
bookPart Parkisionismos atípicos(2021) OLIVEIRA, Marcos Castello Barbosa de; PARMERA, Jacy BezerraconferenceObject The Value of Brain FDG-PET or SPECT in predicting the clinical features of Corticobasal Syndrome(2018) PARMERA, Jacy; ARANHA, Mateus; COUTINHO, Artur; STUDART, Adalberto; ONO, Carla; NITRINI, Ricardo; BUCHPIGUEL, Carlos; BRUCKI, Sonia